Navigation Links
Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Date:9/23/2007

Trial Lays Road Map for Potential Approval of XYOTAX(R) for Women with

Advanced Non-Small Cell Lung Cancer

SEATTLE, Sept. 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) said today it has begun a confirmatory phase III clinical trial of combination chemotherapy for women with advanced non-small cell lung cancer (NSCLC) -- the most lethal cancer facing women today. The trial, known as PGT307, will focus exclusively on women with pre-menopausal estrogen levels -- a group whose survival is significantly shorter than post-menopausal women. XYOTAX (TM) (paclitaxel poliglumex) will be studied in combination with carboplatin versus paclitaxel/carboplatin in female NSCLC patients with performance status of 0, 1, or 2. Paclitaxel in combination with carboplatin is the most commonly used treatment for the estimated 200,000 Americans who are diagnosed with lung cancer each year. The company also announced it received special protocol assessment (SPA) approval from the U.S. Food and Drug Administration (FDA) on the design of the trial.

"In our STELLAR 3 trial we saw a survival benefit in the 70 percent of women who were pre-menopausal, where the XYOTAX/carboplatin combination increased the overall survival of this group by 34 percent over the control arm," said James A. Bianco, M.D., President and CEO of CTI. "This was the basis for PGT307, which can potentially show the important relationship between levels of estrogen and XYOTAX' effectiveness in lung cancer. Lung cancer remains the number one cancer killer of women -- we must ensure that this patient population has access to effective therapies as soon as possible. A successful PGT307 trial will also mean a step forward for gender medicine --a concept too long ignored by the medical establishment."

The PGT307 trial will enroll 450 patients. CTI plans to submit a marketing authorization application (MAA) in Europe in the first half of 2008 for X
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Medical College receives $377K to study brain disease
3. Lucigen receives $750K grant to boost biofuel yields
4. Medical College receives $1.4M cancer grant
5. Wisconsin biotech firm receives $107K NIH grant
6. InvivoSciences receives NIH grant for heart technology
7. Medical College receives $11 million grant to study high blood pressure
8. Madison business receives $115,000 of new state biofuels funding
9. Superior receives funds for technical training
10. UWM receives state funding for plastics research
11. GEs Centricity EHR receives federal certification

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...IK Surgery and vision correction experts listed in...y involved at the recently concluded American Acad...San Francisco, California. Dr. Stephen Brint, MD, ...rf, MD, Dr. Peter Rapoza, MD, Dr. Michael Raizman,...MD, Dr. Edward Manche, MD, and Dr. Parag Majmudar,...
(Date:11/4/2009)...s webinar, which will be presented on November 19 ... flow chemistry processing, will deal with the app...ious meso and micro scale flow chemistry equipment...as been recognized with several prestigious prizes...ahedron Prize. , Columbia...
(Date:11/4/2009)...4 DIATHERIX Laboratories, Inc. (DI...at the Michigan Security Network Homeland Security...ennis Grimaud, Chairman and Chief Executive Office...y,s advanced molecular diagnostic testing on bio-p... diagnosis and military efforts. ,, "This conf...
(Date:11/4/2009)...., Nov. 4 Zyngenia, Inc., a privat...eneration antibody drug development, today announc...ding from New Enterprise Associates (NEA), one of ...ital will be used to create novel, multi-specific ...iological targets with a single agent. The company...
Breaking Biology Technology:Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 2Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 3Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 5Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 6Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 7Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 8Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 9Professor Steven Ley of University of Cambridge will Present Free Webinar, 'Application of the ReactIR Flow Cell to Continuous Processing Technology' 2Professor Steven Ley of University of Cambridge will Present Free Webinar, 'Application of the ReactIR Flow Cell to Continuous Processing Technology' 3DIATHERIX Laboratories Presents at Homeland Security Conference 2Zyngenia, Inc. Raises $10 Million in Series A Funding 2Zyngenia, Inc. Raises $10 Million in Series A Funding 3Zyngenia, Inc. Raises $10 Million in Series A Funding 4
... Young Companies will Present at the Largest Marke...MBRIDGE, Mass., April 22 NSTI and CTSI today anno... for research & development, funding, and comm...h Annual TechConnect Summit, taking place May 4-6,...Houston, Texas. Held in conjunction with the annu...
...INC. (OTC Bulletin Board: ACCP), announced toda...ral mucositis product has been launched in Germany...s European commercial partner, SpePharm, a pan-Eur...o the provision of high medical value medicines in...se from Access Pharmaceuticals Inc, SpePharm is re...
...ent and Innovation , , MOUNTAIN VIEW, Calif., Apr...Sullivan,s Pharmaceuticals & Biotechnology gro... delivery approaches and technologies in cancer tr... insight on factors such as perception, usage, rec...ters, and barriers of leading drug delivery types,...
Other Biology Technology:TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 2TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 3TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 4Access Pharmaceuticals Announces the European Launch of MuGard(TM) by its European Partner, SpePharm 2Access Pharmaceuticals Announces the European Launch of MuGard(TM) by its European Partner, SpePharm 3Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males 2Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males 3
(Date:11/4/2009)...rridors in the cities of Long Beach and Riverside ...eventable childhood asthma, and the true impact of...as likely been underestimated, according to resear...C). , The study, which appears in an online edi...stimated that nine percent of all childhood asthma...
(Date:11/4/2009)...EY, Calif., Oct. 19 Spectros, deve...ng and imaging devices which shed light on life-th...gned exclusive distribution deals for both its T-S...rkets covered include Australia, New Zealand, The...ame, Italy, France, Spain, Portugal, Poland, Greec...
(Date:11/4/2009)...lif., Oct. 23 GenVault Corporation...gement for genomic discovery, medicine and identif... GenVault,s President and CEO, will be presenting ...October 26th and 27th in La Jolla, CA. ,, Durin...rview of the company together with recent customer...
Breaking Biology News(10 mins):USC study finds big air pollution impacts on local communities 2Spectros Signs New International Distribution Deals 2GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2Mylan Launches First Generic Version of Xopenex 28R 29 Inhalation Solution 28Concentrate 29 0 25 25 55877 1Scientists from University of Hawaii at Manoa find genetic marker 55874 1Scientists from University of Hawaii at Manoa find genetic marker 55874 2Promise of nanodiamonds for safer gene therapy 55869 1Promise of nanodiamonds for safer gene therapy 55869 2Promise of nanodiamonds for safer gene therapy 55869 3
... team of Canadian and Finnish scientists has ident...f T-cells, the white blood cells involved in the r...s. The discovery by researchers of the Institute f... Universit de Montral in Canada and the University...on of the journal Immunity could help to combat...
...cientists at The University of Manchester are stri... be used to create stem cell treatments for heart ...ing boost. , All cells that make up the tissues o...are surrounded by a layer of sugars that coat the ... type of cell they are and to respond to the other...
...USTIN, TexasA chemical engineering professor at Th...that has developed a chlorine-tolerant membrane th... increasing access to fresh water and possibly red...ation process more efficient with better membranes... of water, which will expand the availability of c...
Other Biology News:Identification of protein able to stimulate production of T-cells 2Sugar study is sweetener for stem cell science 2New chlorine-tolerant, desalination membrane hopes to boost access to clean water 2
... ProteinPilot Software enables you to identify ove...u can distinguish protein isoforms, protein subset...alize peptide-protein associations and relationshi...ification and relative protein expression analysis...
... Motic's B3 series of microscopes offer all of the...laboratory work. Equipped with Koehler illuminatio...trast (ASC) objectives. The B3 is the workhorse of...cular tube eliminates the need for re-focusing fol...
SYBR Green II RNA gel stain*10,000X concentrate in DMSO**special packaging* from Molecular Probes (Invitrogen)
SYBR Green II RNA gel stain*10,000X concentrate in DMSO* from Molecular Probes (Invitrogen)
Biology Products: